TABLE 4.
Neutralization of pseudoviruses constructed from different env clones
| Serumb | Reciprocal of NA titer againsta:
|
||||||
|---|---|---|---|---|---|---|---|
| MN virus | MN virus-derived pseudovirus:
|
MNE4 | MNE4-derived pseudovirus:
|
||||
| PV-V5 | PV-V32 | PV-V36 | PV-E6 | PV-E14 | |||
| Reference 1 | >5,120 | 4,096 | 2,048 | 2,048 | 8 | 64 | 128 |
| Reference 2 | >5,120 | 4,096 | 4,096 | 2,048 | 128 | 64 | 256 |
| NY-2 | 12,800 | 16,384 | NTd | NT | NT | 512 | NT |
| NY-3c | 25,600 | 8,192 | NT | NT | <8 | 32 | NT |
| NY-4 | 25,600 | 8,192 | NT | NT | <8 | 256 | NT |
| NY-5 | 12,800 | 16,384 | NT | NT | 16 | 16 | NT |
| NY-7 | 6,400 | 8,192 | NT | NT | <8 | 512 | NT |
| NY-8 | 25,600 | 16,384 | NT | NT | NT | 256 | NT |
| NY-9 | 51,200 | ≥32,768 | NT | NT | NT | 512 | NT |
| NY-10 | 6,400 | 16,384 | NT | NT | NT | 512 | NT |
a
Neutralization of MN virus and MNE4 was assayed with Molt 3 cells, and the assays for the pseudoviruses were done with PM1 cells as described in Materials and Methods.
b
Human sera obtained from the NYBC (NY designations) and reference sera were used.
c
Serum that was used for selection of NR variants.
d
NT, not tested.